Neulasta and Neupogen, which are white blood cell boosters, by Amgen Inc. can help to increase the survival chances after the nuclear or radiological attacks, as said by the U.S. Food and Drug Administration (FDA) staff.
Neulasta and Neupogen are given by injection. These are now used by the cancer patients to enhance the infection-fighting white blood cells decreased by chemotherapy treatments. Neulasta is the Amgen’s 2nd best selling drug. Moreover, both of these drugs brought about $5.4 billion in sales last year to the company, as reported by Bloomberg.
“The FDA-approval of a product for use in a radiological/nuclear setting will facilitate access to this product in the event of such an emergency,” FDA staff said in the report.
Researchers from the National Institutes of Health (NIH) worked on monkeys’ exposure to the radiation after giving the dose of Neupogen and presented the findings to the FDA. According to the FDA staff, out of 24 monkeys that were given Neupogen in the study, 79% survived after 60 days, compared with 41% of the 22 monkeys who didn’t take the drug.
“A Joint Meeting of the Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee to be held on May 3, 2013” to talk about the use of this drug in humans.
FDA report, Bloomberg